Geneva Capital Management LLC cut its stake in Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 50.6% in the third quarter, HoldingsChannel.com reports. The fund owned 9,082 shares of the medical research company’s stock after selling 9,295 shares during the period. Geneva Capital Management LLC’s holdings in Edwards Lifesciences were worth $784,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of EW. Legacy Trust grew its holdings in Edwards Lifesciences by 1.4% during the third quarter. Legacy Trust now owns 7,409 shares of the medical research company’s stock valued at $682,000 after purchasing an additional 104 shares during the period. Bessemer Group Inc. grew its holdings in shares of Edwards Lifesciences by 0.4% in the 3rd quarter. Bessemer Group Inc. now owns 28,358 shares of the medical research company’s stock valued at $2,447,000 after buying an additional 114 shares during the period. Flagship Harbor Advisors LLC grew its holdings in shares of Edwards Lifesciences by 1.2% in the 3rd quarter. Flagship Harbor Advisors LLC now owns 10,615 shares of the medical research company’s stock valued at $916,000 after buying an additional 125 shares during the period. Fifth Third Wealth Advisors LLC increased its position in shares of Edwards Lifesciences by 1.8% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 7,268 shares of the medical research company’s stock valued at $627,000 after buying an additional 132 shares in the last quarter. Finally, Calamos Wealth Management LLC raised its stake in Edwards Lifesciences by 6.1% during the 3rd quarter. Calamos Wealth Management LLC now owns 2,438 shares of the medical research company’s stock worth $210,000 after buying an additional 141 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Edwards Lifesciences
In other news, SVP Andrew M. Dahl sold 544 shares of the business’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the sale, the senior vice president directly owned 14,868 shares in the company, valued at $1,353,880.08. The trade was a 3.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Daniel Lippis sold 619 shares of the company’s stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $104.25, for a total value of $64,530.75. Following the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at $4,173,544.50. This represents a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 53,945 shares of company stock worth $5,498,306. Company insiders own 0.31% of the company’s stock.
Edwards Lifesciences Trading Down 0.2%
Shares of NYSE:EW opened at $106.95 on Tuesday. The firm has a market cap of $61.50 billion, a price-to-earnings ratio of 60.42, a PEG ratio of 2.82 and a beta of 0.85. Edwards Lifesciences Corporation has a 12 month low of $74.66 and a 12 month high of $108.00. The company’s fifty day simple moving average is $90.76 and its 200 day simple moving average is $86.44. The company has a quick ratio of 3.86, a current ratio of 4.60 and a debt-to-equity ratio of 0.05.
Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its earnings results on Wednesday, November 4th. The medical research company reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.06. The firm had revenue of $1.72 billion during the quarter, compared to analyst estimates of $1.68 billion. Edwards Lifesciences had a net margin of 15.30% and a return on equity of 16.06%. The company’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.67 EPS. As a group, research analysts forecast that Edwards Lifesciences Corporation will post 3.01 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms have weighed in on EW. Rothschild & Co Redburn lifted their target price on Edwards Lifesciences from $99.00 to $102.00 and gave the stock a “buy” rating in a report on Monday, July 27th. JPMorgan Chase & Co. boosted their target price on Edwards Lifesciences from $105.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, November 5th. Mizuho set a $120.00 price target on Edwards Lifesciences in a report on Thursday, November 5th. Citigroup raised their price target on Edwards Lifesciences from $110.00 to $117.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. Finally, Argus lifted their price objective on Edwards Lifesciences from $105.00 to $115.00 and gave the company a “buy” rating in a report on Friday, August 21st. Twenty-three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $109.88.
View Our Latest Research Report on EW
Edwards Lifesciences Profile
Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.
Read More
- Five stocks we like better than Edwards Lifesciences
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
